Swiss Re AG
DUS:SR9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Swiss Re AG
DUS:SR9
|
CH |
|
B
|
British American Tobacco PLC
XMUN:BMT
|
UK |
|
Entera Bio Ltd
NASDAQ:ENTX
|
IL |
|
S
|
SoftBank Corp
OTC:SFBQF
|
JP |
|
L
|
Laboratory Corporation of America Holdings
F:LAB
|
US |
|
D
|
Devon Energy Corp
DUS:DY6
|
US |
|
ING Groep NV
AEX:INGA
|
NL |
Wall St Price Targets
SR9 Price Targets Summary
Swiss Re AG
According to Wall Street analysts, the average 1-year price target for SR9 is 139.53 EUR with a low forecast of 119.99 EUR and a high forecast of 181.44 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is SR9's stock price target?
Price Target
139.53
EUR
According to Wall Street analysts, the average 1-year price target for SR9 is 139.53 EUR with a low forecast of 119.99 EUR and a high forecast of 181.44 EUR.
What is the Revenue forecast for Swiss Re AG?
Projected CAGR
5%
Over the last 14 years, the compound annual growth rate for Revenue has been 3%. The projected CAGR for the next 2 years is 5%.
What is the Net Income forecast for Swiss Re AG?
Projected CAGR
2%
Over the last 14 years, the compound annual growth rate for Net Income has been 4%. The projected CAGR for the next 2 years is 2%.
